← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Per Wold-Olsen
Styrelseordförande
Profile key: se|per wold-olsen
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 1
- Purchases · 24M
- 9
- Average purchase
- SEK 466,490
- Gross purchase value
- SEK 4,198,413
- Last purchase
- 2026-03-17
- Completed 20D events
- 8.0
- Outcome status
- PASS
Latest company: Oncopeptides AB
Companies: Oncopeptides AB | Senzime AB | Senzime AB (publ.)
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -4.9% | -4.5% | -7.2% |
| 20D | 8Developing | 100.0% (8/8) | 25.0% (2/8) | -10.3% | -8.3% | -21.0% |
| 60D | 8Developing | 100.0% (8/8) | 37.5% (3/8) | -6.2% | -4.7% | -23.4% |
| 120D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -16.9% | -34.2% | -85.6% |
Research patterns
- First purchase in 12M
- 1/7
- Large purchase ≥ €100k
- 1/8
- Cluster buying · 15D
- 0/8
- Buying the dip · ≥20% below prior 52W high
- 7/8
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.